Lupin has received an FDA approval for its cholesterol drug, Nikita Pitavastatin. The drug, which received a new drug approval from the agency, is poised as the latest treatment for patients suffering from primary hyperlipidemia or mixed dyslipidemia by lowering total elevated cholesterol, low density lipoprotein cholesterol, apolipoprotein B, and triglycerides while increasing high-density lipoprotein cholesterol.